| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA776: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea |
|
Medicine details |
|
| Medicine name | pitolisant hydrochloride (Ozawade®) |
| Formulation | 4.5 mg, 18 mg film coated tablet |
| Reference number | 2671 |
| Indication | Improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). |
| Company | Bioprojet Pharma Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/07/2021 |
| NICE guidance | |